Harnessing the natural cellular process of autophagy to design powerful new medicines


Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to intervene at strategic points throughout the autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens. By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications.


Year Invested: 2018
Location: Cambridge, MA
Visit: www.casmatx.com/

Recent News

September 11, 2018
Casma Therapeutics Announces Partnership with Fondazione Telethon, Founder of the Telethon Institute of Genetics and Medicine (TIGEM)

August 6, 2018
Casma Therapeutics Expands Executive Team with Appointment of Two Senior Vice Presidents

May 30, 2018
Casma Therapeutics Co-Founder Reports Health Benefits of Increased Autophagy in Mammals in Nature Publication

Read More News

Associated Team Members

Cary Pfeffer, M.D.
Partner

Frank T. Gentile, Ph.D.
Venture Partner

Robert Tepper, M.D.
Partner